一种可能改进的血浆亚甲蓝病毒灭活方法：Maco Pharma公司的Maco-Tronic系统。

A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system.

作者信息

Hornsey V S, Drummond O, Young D, Docherty A, Prowse C V

机构信息

Transfusion Service, National Science Laboratory, Edinburgh, UK.

出版信息

Transfus Med. 2001 Feb;11(1):31-6. doi: 10.1046/j.1365-3148.2001.00282.x.

DOI:10.1046/j.1365-3148.2001.00282.x

PMID:11328569

Abstract

Plasma was subjected to methylene blue (MB) photochemical virus inactivation using the Maco Pharma Maco-Tronic system which allows three units to be illuminated together, thus reducing processing time. The plasma bag system used incorporates an integral membrane plasma filter and a dry MB pill which dissolves in the plasma to give a 1-microM concentration. There is computer-controlled processing and datalogging. In an assessment of 10 pools of Group A plasma, the losses of coagulation factors, following MB/light treatment, were 23% fibrinogen, 10% FV, 26% FVIII, 11% FIX and 13% FXI. Group O, Group B and Group AB plasmas were not tested. Von Willebrand factor (vWf) multimers showed no substantial change when treated with MB, and no losses were seen for antithrombin III (ATIII), protein C and vWf:Ag. Measurements of C3a, C5a, prothrombin fragment 1+2 and FXIIa indicated that there was no activation as a result of filtration.

摘要

使用Maco Pharma公司的Maco-Tronic系统对血浆进行亚甲蓝（MB）光化学病毒灭活，该系统可同时照射三个单元，从而缩短处理时间。所使用的血浆袋系统包含一个一体式膜血浆过滤器和一粒可溶解于血浆中的干燥MB药丸，以达到1微摩尔的浓度。处理过程由计算机控制并进行数据记录。在对10组A型血浆的评估中，MB/光照处理后凝血因子的损失情况为：纤维蛋白原损失23%，FV损失10%，FVIII损失26%，FIX损失11%，FXI损失13%。未对O型、B型和AB型血浆进行测试。用MB处理后，血管性血友病因子（vWf）多聚体无显著变化，抗凝血酶III（ATIII）、蛋白C和vWf:Ag也无损失。C3a、C5a、凝血酶原片段1+2和FXIIa的测量结果表明，过滤未导致激活。